Mar-16 -

Leukemia Group

EORTC 06031 – Gemtuzumab ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy : a randomized phase II/III trial (AML-19) of the EORTC-LG and GIMEMA-ALWP.

EORTC found that low-dose of gentuzumab ozogamicin (GO), compared with best supportive care, prolonged survival without serious adverse effects in elderly patients with acute myelogenous leukemia (AML), who were ineligible for intensive chemotherapy.


Go to Top